Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

27 October 2021

BioNTech to Report Third Quarter Financial Results and Operational Update on No..

26 October 2021

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization f..

26 October 2021

BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing F..

Press releases (more)

Upcoming Events

November 1 - November 3, 2021

Citi China Investor Conference

November 9, 2021 at 8:00 AM EST

Third Quarter 2021 Earnings Call

November 16 - November 18, 2021

Jefferies London Healthcare Conference

Upcoming events (more)

Stock Quote

Oct 27, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.